Protective role of TNF-α in respiratory syncytial virus infection in vitro and in vivo

American Journal of the Medical Sciences

Volumn 311, Issue 5, 1996, Pages 201-204

  Neuzil, Kathleen M ^a   Tang, Yi Wei ^a   Graham, Barney S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunopathogenesis; Murine model; Respiratory syncytial virus; Tumor necrosis factor alpha

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HEP 2 CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MOUSE; NONHUMAN; PROTECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION; VIRUS PLAQUE; VIRUS REPLICATION; WEIGHT REDUCTION;

EID: 0029940874     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199605000-00001     Document Type: Article

References (22)

1. Hall CB, McCarthy CA. Respiratory syncytial virus. In: Mandell G, Douglas G, Dolin R, ed. Principles and Practices of Infectious Diseases, 4th ed. New York: Churchill Livingstone; 1995: 1501-19.
2. Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Moller A, et al. Antiviral effects of recombinant tumour necrosis factor in vitro. Nature. 1986;323:816-9.
3. Wong GH, Krowka J, Stites DP, Goeddel DV. In vitro antihuman immunodeficiency virus activities of tumor necrosis factor-α and interferon-α. J Immunol. 1988;140:120-4.
4. Wong GH, Goeddel DV. Tumour necrosis factors α and βinhibit virus replication and synergize with interferons. Nature. 1986;323:819-22.
5. 1 and the 26-kDa protein as mediators of the antiviral effect of interleukin 1 and tumor necrosis factor. J Immunol. 1987;139:1867-72.
6. Wong GH, McHugh T, Weber R, Goeddel DV. Tumor necrosis factor α selectively sensitizes human immunodeficiency virus-infected cells to heat and radiation. Proc Natl Acad Sci U S A. 1991;88:4372-6.
7. Wong GH, Tartaglia LA, Lee MS, Goeddel DV. Antiviral activity of tumor necrosis factor is signaled through the 55-kDa receptor, type I TNF. J Immunol. 1992;149:3350-3.
8. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun. 1988;56:2563-9.
9. Blanchard DK, Djeu JY, Klein TW, Friedman H, Stewart WE. Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leuk Biol. 1988;43:429-35.
10. Titus RG, Sherry B, Cermi A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med. 1989;170:2097-104.
11. Rothe J, Lessiauer W, Lotschef H, Lang Y, Koebel P, Kontgen F, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364: 798-802.
12. Sambhi SK, Kohonen-Corish MR, Ramshaw IA. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci USA. 1991;88:4025-9.
13. Tufariello J, Cho S, Horwitz MS. The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model. J Virol. 1994;68:453-62.
14. 2. Am J Physiol. 1990;3:L396-402.
15. Hayes PJ, Scott R, Wheeler J. In vivo production of tumour necrosis factor-α and interleukin-6 in BALB/c mice inoculated intranasally with a high dose of respiratory syncytial virus. J Med Virol. 1994;42:323-9.
16. Midulla F, Huang YT, Gilbert IA, Cirino NM, McFadden ER, Panuska JR. Respiratory syncytial virus infection of human cord and adult blood monocytes and alveolar macrophages. Am Rev Respir Dis. 1989;140:771-7.
17. Franke G, Freihorst J, Steinmuller C, Verhagen W, Hockertz S, Lohmann-Matthes ML. Interaction of alveolar macrophages and respiratory syncytial virus. J Immunol Methods. 1994;174:173-84.
18. Becker S, Quay J, Soukup J. Cytokine (tumor necrosis factor, IL-6, IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol. 1991;147:4307-12.
19. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol. 1988;26: 153-62.
20. Arnold R, Humbert B, Werchau H, Gallati H, Konig W. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology. 1994;82:126-33.
21. Scharton TM, Scott P. Natural killer cells are a source of interferon-τ that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med. 1993;178:567-77.
22. Orange JS, Salazar-Mather TP, Opal SM, Spencer RL, Miller AH, McEwen BS, et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: Role of tumor necrosis factor and glucocorticoids. J Exp Med. 1995;181: 901-14.